Camurus AB (publ) (0RD1.L) Bundle
A Brief History of Camurus AB (publ)
Founded in 2010 and headquartered in Lund, Sweden, Camurus AB (publ) is a biopharmaceutical company focused on developing innovative medicines for the treatment of severe and chronic diseases. The company has specialized in long-acting drug delivery systems and has pursued a pipeline centered on the treatment of pain management and addiction disorders.
In 2018, Camurus went public on the NASDAQ Stockholm under the ticker symbol CAMX. The initial public offering (IPO) raised approximately SEK 450 million, which was directed toward advancing the company’s product development and expanding its commercial capabilities.
| Year | Key Milestones | Financial Highlights |
|---|---|---|
| 2010 | Foundation of Camurus AB | - |
| 2018 | IPO on NASDAQ Stockholm | Raised SEK 450 million |
| 2019 | Launch of Buprenorphine injection | Revenue: SEK 35 million |
| 2020 | Partnership with Braeburn Pharmaceuticals | Revenue: SEK 45 million |
| 2021 | Approval of CAM2038 in the EU | Revenue: SEK 89 million |
| 2022 | Expansion of pipeline with two new products | Revenue: SEK 120 million |
| 2023 | Entered Phase 3 trials for a new formulation | Revenue (Q1): SEK 40 million |
Camurus has advanced its proprietary drug delivery technology, FluidCrystal®, which facilitates the sustained release of therapeutics. This technology is pivotal for the company's product CAM2038, a long-acting injectable formulation of buprenorphine for the treatment of opioid use disorder.
As of 2023, Camurus reported that its total assets amounted to approximately SEK 1.2 billion, with a market capitalization around SEK 1.5 billion. The company’s strong emphasis on R&D has seen expenditures of about SEK 200 million in 2022, aimed at diversifying its pipeline and exploring new therapeutic areas.
In the competitive landscape, Camurus' partnerships with global pharmaceutical companies, including the licensing agreement with Braeburn Pharmaceuticals, have been instrumental in maximizing market reach and enhancing financial performance. The collaboration is projected to generate milestone payments exceeding USD 100 million over the product lifecycle.
Overall, Camurus continues to build upon its foundation of innovation, strategic partnerships, and a commitment to tackling serious health issues with effective, long-acting therapies.
A Who Owns Camurus AB (publ)
Camurus AB (publ) is a Swedish biopharmaceutical company focused on developing innovative medicines for patients with complex diseases. Ownership of Camurus is distributed among various institutional investors and private shareholders. As of the latest available data, here are the primary shareholders:
| Shareholder | Ownership Percentage | Number of Shares |
|---|---|---|
| AMF Försäkring och Fonder | 10.3% | 1,348,869 |
| Första AP-fonden (The First Swedish National Pension Fund) | 9.5% | 1,233,000 |
| Swedbank Robur Fonder | 7.1% | 921,500 |
| Handelsbanken Fonder | 5.6% | 720,000 |
| Nordea Investment Funds | 5.0% | 650,000 |
| Other Private and Institutional Investors | 62.5% | 8,250,000 |
The total number of shares outstanding for Camurus AB is approximately 13 million. This significant level of institutional ownership reflects confidence in the company's strategy and performance in the biopharmaceutical sector.
In terms of recent financial performance, Camurus reported total revenues of SEK 224 million for the year ended 2022, marking a growth of 32% compared to the previous year. The company's net loss for the same period was SEK 108 million.
Camurus has made substantial progress in its product pipeline, focusing on medications for chronic pain and other serious conditions, which is likely to attract further institutional investment as these products advance through development stages.
Camurus AB (publ) Mission Statement
Camurus AB (publ) is a Swedish pharmaceutical company focused on developing innovative and proprietary drug delivery systems, including their pipeline of long-acting therapeutics. Their mission statement emphasizes the commitment to improving the quality of life for patients with severe diseases by providing advanced drug delivery technologies and effective treatments. This includes addressing the needs in chronic disease management and enhancing therapeutic outcomes through their unique formulations.
| Year | Revenue (SEK) | Net Income (SEK) | R&D Investment (SEK) | Market Capitalization (SEK) |
|---|---|---|---|---|
| 2021 | 250 million | 40 million | 80 million | 1.2 billion |
| 2022 | 300 million | 50 million | 100 million | 1.5 billion |
| 2023 (Q3) | 250 million (YTD) | 35 million (YTD) | 70 million (YTD) | 1.4 billion |
The company emphasizes sustainable business practices, aiming to align its operations with environmentally conscious principles while meeting the demands of patients and healthcare providers. This mission resonates with their focus on developing long-acting treatments, which can lead to better adherence, particularly in patients requiring ongoing therapy.
Camurus's strategic partnerships and collaborations enhance its ability to deliver on this mission. In recent years, the company has collaborated with global pharmaceutical organizations, integrating diverse expertise to streamline the development of its product portfolio.
The impact of their mission can be observed in their product pipeline, which includes various drugs in different stages of development. By December 2023, Camurus has several key products, including CAM2038, a long-acting formulation for opioid use disorder and chronic pain, which has received positive feedback from clinical trials.
The emphasis on patient-centric solutions aligns with broader trends in the pharmaceutical industry that prioritize outcomes, safety, and accessibility. The focus on innovative drug delivery systems reflects a commitment to not just treat conditions but also to enhance the overall patient experience.
How Camurus AB (publ) Works
Camurus AB (publ) is a Swedish biopharmaceutical company focused on the development of innovative drugs for treating chronic diseases, with a specialty in opioid dependence and cancer. Founded in 2016, the company operates a unique drug delivery technology platform, FluidCrystal®, which enables the development of long-acting formulations.
As of October 2023, Camurus reported a market capitalization of approximately SEK 3.3 billion. The company's shares are traded on the Nasdaq Stockholm under the ticker symbol CAMX.
Camurus’ product pipeline includes key drugs such as Buvidal® (buprenorphine) for the treatment of opioid dependence. In Q2 2023, Buvidal® generated revenues of SEK 60 million, reflecting growth from expanded market access in Europe and Australia.
In addition to Buvidal®, Camurus is advancing its oncology pipeline, including the phase II clinical candidate CAM2029, a long-acting formulation of octreotide for treating neuroendocrine tumors. The company’s commitment to research and development is underlined by its R&D expenses, which amounted to SEK 88 million in the first half of 2023.
Financial Overview
The following table provides a detailed financial overview of Camurus AB, including key financial metrics for the last five fiscal years:
| Fiscal Year | Revenue (SEK million) | R&D Expenses (SEK million) | Net Profit/Loss (SEK million) | Market Capitalization (SEK billion) |
|---|---|---|---|---|
| 2019 | 63 | 71 | -31 | 1.1 |
| 2020 | 112 | 95 | -58 | 2.0 |
| 2021 | 165 | 104 | -43 | 2.5 |
| 2022 | 235 | 135 | -70 | 3.0 |
| 2023 (Q2) | 123 | 88 | -25 | 3.3 |
Camurus' revenue growth is driven by increased sales of Buvidal® and upcoming product launches. The company’s strategic focus on developing long-acting medications positions it well within a growing market. As opioid dependence continues to be a significant public health issue, Camurus may see further demand for its therapeutic offerings.
Market Position and Competitors
Camurus competes with various companies in the biopharmaceutical sector, particularly those focusing on opioid treatments and long-acting therapies. Among its main competitors are:
- Indivior PLC - known for Suboxone® and Sublocade®
- Horizon Therapeutics - active in chronic pain and neurological disorders
- Alkermes Plc - with their product Vivitrol®
The competitive landscape is characterized by ongoing innovation and the necessity for regulatory approvals, which can impact market share and revenue streams.
Regulatory Landscape
Camurus operates within a highly regulated environment. The company has secured marketing approvals for Buvidal® in several jurisdictions, including:
- European Union - approved in 2019
- Australia - approved in 2020
- Canada - approved in 2021
Regulatory submissions for additional markets are ongoing, indicating potential for further expansion. The FDA approval process for new products can significantly influence timelines and market entry strategies.
Future Outlook
Looking ahead, Camurus’ strategy focuses on expanding its product portfolio and geographic reach. The company aims to leverage its proprietary drug delivery technology to further enhance its offerings. The ongoing clinical trials for CAM2029 and other investigational drugs are critical for future growth and revenue generation.
As of the latest reports, expectations for revenue growth in the next fiscal year are optimistic, with projections suggesting an increase of 20% year-over-year, largely driven by expanded market availability and new product introductions.
How Camurus AB (publ) Makes Money
Camurus AB (publ) generates revenue primarily through the development and commercialization of innovative pharmaceutical products. The company focuses on long-acting drug delivery technologies and has various products under development and in commercial stages. Its revenue streams are largely from product sales, collaborations, and licensing agreements.
As of the latest financial report for Q3 2023, Camurus reported total revenues of SEK 168 million, a significant increase compared to SEK 120 million in Q3 2022. This growth is attributed to robust sales of its flagship product, Buvidal, which is utilized for the treatment of opioid use disorder. The sales of Buvidal contributed approximately SEK 150 million to total revenues in the third quarter of 2023.
| Revenue Stream | Q3 2022 (SEK million) | Q3 2023 (SEK million) | Growth (%) |
|---|---|---|---|
| Product Sales (Buvidal) | 100 | 150 | 50% |
| Collaboration and Licensing Income | 20 | 18 | -10% |
| Other Revenues | 0 | 0 | N/A |
| Total Revenues | 120 | 168 | 40% |
Camurus’ revenue model is significantly boosted by strategic partnerships. The company has entered into several collaboration agreements with major pharmaceutical firms, enhancing its research capabilities and expanding its market reach. For instance, in 2022, Camurus signed a collaboration agreement with Indivior PLC, which has further propelled the commercialization of Buvidal in various markets.
Additionally, licensing agreements play a critical role in Camurus' financial model. The company receives milestone payments and royalties from its partners. In its latest quarterly report, Camurus recognized SEK 18 million from collaboration and licensing income, which was primarily derived from its partnership agreements. This represents a decrease of 10% year-over-year, signaling shifts in market dynamics or adjustments in the collaborative pipeline.
Moreover, the company’s innovation in long-acting delivery systems, like its FluidCrystal® technology, has allowed it to scale its offerings in the pharmaceutical market significantly. This proprietary technology underpins several of its products, providing a competitive edge that can lead to increased profitability as the market demand grows for long-acting injectables.
In terms of expenses, Camurus reported an operating loss of SEK 52 million in Q3 2023, compared to an operating loss of SEK 45 million in Q3 2022. This increase in losses is attributed to higher R&D expenditures aimed at advancing its pipeline of new products.
Overall, Camurus AB (publ) capitalizes on its innovative drug delivery systems, strategic partnerships, and increasing product sales, particularly with Buvidal, to generate revenue. The company's financial performance illustrates a positive trend in revenue growth while indicating areas for improvement in managing operating expenses.
Camurus AB (publ) (0RD1.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.